BioCentury | Jul 11, 2016
Clinical News

Ryzodeg insulin degludec/insulin aspart regulatory update

...EMA’s CHMP recommended expanding the label of Ryzodeg insulin degludec/insulin aspart from Novo Nordisk to treat Type I...
...Nordisk to treat Type I and Type II diabetes to include pediatric patients ages >=2. Ryzodeg...
...NYSE:NVO), Bagsvaerd, Denmark Product: Ryzodeg insulin degludec /insulin aspart ( DegludecPlus , IDegAsp ) ( NN5401...
BioCentury | Oct 5, 2015
Finance

Drawn and quartered

...reduced ejection fraction Novo Nordisk A/S (NYSE:NVO; CSE:NVO) FDA approves Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart...
BioCentury | Oct 5, 2015
Clinical News

Ryzodeg insulin degludec/insulin aspart regulatory update

...FDA approved NDAs from Novo Nordisk for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart to improve glycemic...
...a full commercial launch planned for 1Q16; a launch timeline has not been set for Ryzodeg...
...NYSE:NVO), Bagsvaerd, Denmark Product: Ryzodeg insulin degludec /insulin aspart ( DegludecPlus , IDegAsp ) ( NN5401...
BioCentury | Oct 5, 2015
Clinical News

Tresiba insulin degludec regulatory update

...FDA approved NDAs from Novo Nordisk for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart to improve glycemic...
...a full commercial launch planned for 1Q16; a launch timeline has not been set for Ryzodeg...
...“for a few weeks” (see BioCentury, April 13). Tresiba is a long-acting insulin analog, and Ryzodeg...
BioCentury | Sep 25, 2015
Company News

FDA approves Novo's Tresiba, Ryzodeg

...FDA approved both Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart from Novo Nordisk A/S (NYSE:NVO; CSE:NVO) to...
...BioCentury Tresiba would launch in early 2016; a launch timeline has not been set for Ryzodeg...
...prices would not be available "for a few weeks." Novo resubmitted NDAs for Tresiba and Ryzodeg...
BioCentury | Aug 7, 2015
Company News

Novo reports weakening diabetes sales in China

...insulin degludec , which has completed a Phase III trial in China, and eventually Ryzodeg insulin degludec/insulin aspart...
BioCentury | Apr 13, 2015
Clinical News

Ryzodeg insulin degludec/insulin aspart regulatory update

...Nordisk said FDA accepted for review 2 resubmitted NDAs for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart...
...Ryzodeg are marketed in the EU and Japan. Tresiba is a long-acting insulin analog, and Ryzodeg...
...NYSE:NVO), Bagsvaerd, Denmark Product: Ryzodeg insulin degludec /insulin aspart ( DegludecPlus , IDegAsp ) ( NN5401...
BioCentury | Apr 13, 2015
Clinical News

Tresiba insulin degludec regulatory update

...Nordisk said FDA accepted for review 2 resubmitted NDAs for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart...
...Ryzodeg are marketed in the EU and Japan. Tresiba is a long-acting insulin analog, and Ryzodeg...
BioCentury | Apr 8, 2015
Company News

FDA again reviewing Novo insulins

...CSE:NVO; NYSE:NVO) said FDA accepted for review resubmitted NDAs for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart...
...and Ryzodeg are approved in Europe and Japan. Tresiba is a long-acting insulin analog and Ryzodeg...
BioCentury | Oct 6, 2014
Company News

Novo Nordisk sales and marketing update

...Novo Nordisk launched Ryzodeg insulin degludec /insulin aspart in Mexico to treat Type II diabetes. Novo...
...Mexico to treat Type II diabetes. Novo Nordisk said Mexico is the first country where Ryzodeg...
...and that it plans to launch the product in additional countries within the next year. Ryzodeg...
Items per page:
1 - 10 of 67